Received Apr 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | N4TY2 | — |
administration of Menveo 1 vial plus only liquid portion of Menveo 2 vials; administration of Menveo 1 vial plus only liquid portion of Menveo 2 vials; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 20-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB094A) and (batch number N4TY2) for prophylaxis. On 27-MAR-2026, the patient received Menveo. On 27-MAR-2026, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: administration of Menveo 1 vial plus only liquid portion of Menveo 2 vials) and inappropriate dose of vaccine administered (Verbatim: administration of Menveo 1 vial plus only liquid portion of Menveo 2 vials). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 31-MAR-2026 Registered nurse called to report that the liquids from both presentations were mixed and administered to the patient. The reporter contacted to ask whether the patient was covered. The vaccine administration facility was the same as the primary reporter. The health care professional stated that, based on their inventory, the Menveo 1-vial and 2-vial presentations had been mixed and indicated that they were not fully certain whether the patient received the mixed liquid; however, confirmation of coverage was requested.